Chinese biotech firm Immunotech deploys IPO cash to bet on next technology to fight liver cancer

Immunotech Biopharm expects to collect results from its clinical trials on liver-cancer patients next year and aims to win marketing approval for its technology in 2022, CEO Wang Yu says.
( read original story …)